AU2015389862B2 - Use of thia oxo compounds for lowering Apo C3 - Google Patents

Use of thia oxo compounds for lowering Apo C3 Download PDF

Info

Publication number
AU2015389862B2
AU2015389862B2 AU2015389862A AU2015389862A AU2015389862B2 AU 2015389862 B2 AU2015389862 B2 AU 2015389862B2 AU 2015389862 A AU2015389862 A AU 2015389862A AU 2015389862 A AU2015389862 A AU 2015389862A AU 2015389862 B2 AU2015389862 B2 AU 2015389862B2
Authority
AU
Australia
Prior art keywords
subject
compound
formula
apoc
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015389862A
Other languages
English (en)
Other versions
AU2015389862A1 (en
Inventor
David Alan Fraser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pronova Biopharma Norge AS
Original Assignee
Pronova Biopharma Norge AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge AS filed Critical Pronova Biopharma Norge AS
Publication of AU2015389862A1 publication Critical patent/AU2015389862A1/en
Application granted granted Critical
Publication of AU2015389862B2 publication Critical patent/AU2015389862B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU2015389862A 2015-04-01 2015-04-01 Use of thia oxo compounds for lowering Apo C3 Active AU2015389862B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/001316 WO2016156912A1 (en) 2015-04-01 2015-04-01 Use of thia oxo compounds for lowering apo c3

Publications (2)

Publication Number Publication Date
AU2015389862A1 AU2015389862A1 (en) 2017-11-23
AU2015389862B2 true AU2015389862B2 (en) 2021-04-15

Family

ID=53879725

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015389862A Active AU2015389862B2 (en) 2015-04-01 2015-04-01 Use of thia oxo compounds for lowering Apo C3

Country Status (7)

Country Link
US (1) US20180110747A1 (enExample)
JP (1) JP2018510206A (enExample)
KR (1) KR20180010181A (enExample)
AU (1) AU2015389862B2 (enExample)
MX (1) MX388141B (enExample)
RU (1) RU2705991C2 (enExample)
WO (1) WO2016156912A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
IL308604B2 (en) 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
KR20210015883A (ko) 2018-05-23 2021-02-10 노스씨 테라퓨틱스 비.브이. 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산
JP2023554524A (ja) 2020-12-22 2023-12-27 ノースシー セラピューティクス ベスローテン フェンノートシャップ 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128401A1 (en) * 2009-05-08 2010-11-11 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
WO2012059818A1 (en) * 2010-11-05 2012-05-10 Pronova Biopharma Norge As Methods of treatment using lipid compounds
US20130295173A1 (en) * 2012-05-07 2013-11-07 Omthera Pharmaceuticals, Inc. Compositions of statins and omega-3 fatty acids
WO2014132134A1 (en) * 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128401A1 (en) * 2009-05-08 2010-11-11 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
WO2012059818A1 (en) * 2010-11-05 2012-05-10 Pronova Biopharma Norge As Methods of treatment using lipid compounds
US20130295173A1 (en) * 2012-05-07 2013-11-07 Omthera Pharmaceuticals, Inc. Compositions of statins and omega-3 fatty acids
WO2014132134A1 (en) * 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same

Also Published As

Publication number Publication date
MX388141B (es) 2025-03-19
AU2015389862A1 (en) 2017-11-23
US20180110747A1 (en) 2018-04-26
RU2705991C2 (ru) 2019-11-13
JP2018510206A (ja) 2018-04-12
MX2017012641A (es) 2018-06-06
KR20180010181A (ko) 2018-01-30
RU2017137960A3 (enExample) 2019-05-06
WO2016156912A1 (en) 2016-10-06
RU2017137960A (ru) 2019-05-06

Similar Documents

Publication Publication Date Title
US12440466B2 (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis
AU2021204406B2 (en) Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
EP2635270B1 (en) Methods of treatment using lipid compounds
US20180110747A1 (en) Use of thia oxo compounds for lowering apo c3
CA2886957C (en) Use of thia oxo compounds for lowering apo c3
JP7341916B2 (ja) アポｃ３を低下させるためのチアオキソ化合物の使用
BR102015007435A2 (pt) uso de compostos tia oxo para diminuir apo c3
RU2820995C2 (ru) Структурно усиленные жирные кислоты, содержащие кислород, для лечения неалкогольного стеатогепатита
CA3201254A1 (en) Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis
HK40037101B (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis
HK40037101A (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)